All In Biotech

Drug Trial Radar · NCT02087306

Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection

A Phase 3, Open-Label, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection

Last checked: Nov 19, 2026Latest source record: Aug 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

201

Actual

Start

Mar 2014

Primary completion

Jun 2016

Study completion Aug 2016

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
First posted
Mar 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 3 open-label, non-randomized, multicenter study of oral brincidofovir (BCV) administered twice weekly for the treatment of adenovirus (AdV) infection detected during asymptomatic AdV viremia or during symptomatic AdV infection.

Conditions

  • Adenovirus Infection

Interventions

  • BrincidofovirDrug

    BCV administered twice weekly, dose depending on weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With All-Cause MortalityTime frame: 60 days

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Stanford Children's Hospital

    Palo Alto, California

  • Stanford University

    Stanford, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Children's National Health System

    Washington D.C., District of Columbia

  • Children's Healthcare of Atlanta, Aflac Cancer and Blood Center

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Children's Hospital

    New Orleans, Louisiana

  • Johns Hopkins University

    Baltimore, Maryland

  • Brigham and Woman's Hospital

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Children's Mercy Hospital

    Kansas City, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska

    Omaha, Nebraska

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Weill Cornell Medical College/ New York Presbyterian Hospital

    New York, New York

  • Montifore Medical Center

    The Bronx, New York

  • Levine Children's Hospital

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • St. Jude Children's Hospital

    Memphis, Tennessee

  • Cook Children's Medical Center

    Fort Worth, Texas

  • Baylor College of Medicine

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Intermountain Healthcare Research

    Salt Lake City, Utah

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah

  • Fred Hutchingson Cancer Center

    Seattle, Washington

  • Seattle Children's Hospital

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.